Shivalik Rasayan

Shivalik Rasayan allotted 2,82,000 equity shares at Rs250 each for Rs7.05 crore to five public investors and 9,47,990 fully convertible warrants at Rs250 each for Rs23.70 crore to Growel Remedies, Bishnoi Exports and Ginnerup Capital ApS on 14 September 2026. Paid-up capital rose to 1,60,32,365 shares of Rs5 each, with fully diluted capital at 1,69,80,355 shares upon warrant conversion. Capital stood at 1,57,50,365 shares after conversion of 1,90,000 warrants at Rs716 in March 2025, with Growel Remedies holding 47.37%. Standalone sales were Rs170.23 crore in FY26 alongside consolidated sales of Rs368.0 crore, while the Dahej-III agro plant of 2,500 MT was operational since September 2024 and the Dahej-II API plant held US FDA approval from October 2024.

Powered by Tijori

Shivalik Rasayan Limited's board on July 23, 2026, approved a preferential issue of up to 3.72 lakh equity shares and 9.48 lakh fully convertible warrants, each priced at ₹250, raising a total of about ₹33 crore. The equity shares will be allotted to five public investors, while the warrants are issued to promoter entity Growel Remedies, Bishnoi Exports Private Limited, and Denmark‐based Ginnerup Capital ApS. The warrants can be converted into an equal number of equity shares within 18 months of allotment. The fundraising is subject to shareholder approval, with an extraordinary general meeting scheduled for August 20, 2026. A preferential issue committee will handle the documentation.

Powered by Tijori

May 27 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• SHIVALIK RASAYAN LTD MARCH-QUARTER CONSOL NET PROFIT 45.3 MILLION RUPEES

• SHIVALIK RASAYAN LTD MARCH-QUARTER CONSOL INCOME FROM OPERATIONS 1.03 BILLION RUPEES

Further company coverage: SIVA.NS

(([email protected];))

Oct 3 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• US FDA APPROVED API FACILITY OF SHIVALIK RASAYAN AT DAHEJ

• US FDA RELEASED ESTABLISHMENT INSPECTION REPORT FOR DAHEJ INSPECTION

Source text for Eikon: ID:nBSE6BVxKL

Further company coverage: SIVA.NS

(([email protected];;))

** Shares of agrochemicals and active pharma ingredients (API) maker Shivalik Rasayan SIVA.NS rise 5% to 590.35 rupees

** Co says U.S. Food and Drug Administration completed inspection at its Dahej factory, Gujarat, with seven procedural observations

** Shares down 20% YTD after falling 2.6% in 2023

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

April 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• SHIVALIK RASAYAN LTD - COMPLETION OF US FDA INSPECTION AT API FACILITY OF SHIVALIK RASAYAN LIMITED AT DAHEJ UNIT

• SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY

• SHIVALIK RASAYAN LTD - INSPECTION CLOSED SUCCESSFULLY WITH 7 OBSERVATIONS ONLY

Source text for Eikon: ID:nBSE6fcsV1

Further company coverage: SIVA.NS

(([email protected];;))

March 26 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• APPROVALS TO CONSTRUCT RG-4 AT DAHEJ UNIT-I ARE RECEIVED FROM GIDC

• VENDORS/ CONTRACTORS ARE FINALISED AND CONSTRUCTION ACTIVITIES STARTED

Source text for Eikon: ID:nBSEb4Ll6P

Further company coverage: SIVA.NS

(([email protected];))

** Shares of Shivalik Rasayan SIVA.NS rise 5% to 582.7 rupees

** Co received all required licenses to start manufacturing at newly built agro-chemical plant

** Commercial production to start from April

** Stock snaps three consecutive sessions of fall

** More than 41,000 shares change hands, 2.5x its 30-day avg

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Jan 9 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• RECEIVED CERTIFICATE OF SUITABILITY FOR PIRFENIDONE FROM EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINE & HEALTHCARE

Further company coverage: SIVA.NS

(([email protected];))

Aug 8 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• RE-APPOINTS DR. VIMAL KUMAR SHRAWAT AS MANAGING DIRECTOR

Source text for Eikon: ID:nNSE1HL4BC

Further company coverage: SIVA.NS

(([email protected];))

July 28 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• CENTRE FOR DRUG EVALUATION, CHINA HAS ACKNOWLEDGED DRUG MASTER FILE OF BENDAMUSTINE API

• PROCESS OF EVALUATIONS AND APPROVAL IS UNDERWAY

Source text for Eikon: ID:nBSE5LPzN7

Further company coverage: SIVA.NS

(([email protected];))

July 19 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• ISSUED LOA TO MEDICAMEN BIOTECH, TO USE DMF GRADE BORTEZOMIB API FOR FORMULATION OF BORTEZOMIB INJECTION 3.5MG/ VIAL

Source text for Eikon: ID:nBSE219bhg

Further company coverage: SIVA.NS

(([email protected];;))

May 30 (Reuters) - Shivalik Rasayan Ltd SIVA.NS:

• SHIVALIK RASAYAN LTD - TO CONSIDER PROPOSAL FOR RAISING FUNDS

Source text for Eikon: ID:nBSEDksnd

Further company coverage: SIVA.NS

(([email protected];))